Clinical Trial Update: Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

View source ↗

Summary

This clinical trial update reports urinary retention rates observed in real-world practice after treatment with onabotulinumtoxinA for idiopathic overactive bla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Botox (OnabotulinumtoxinA)

Snippet

Sponsor: Allergan | Conditions: Urinary Bladder, Overactive | Status: COMPLETED